In Malaysia, generic drugs are registered through the National Pharmaceutical Regulatory Agency (NPRA). Manufacturers must submit a dossier including bioequivalence studies, quality, safety, and efficacy data. The NPRA evaluates these submissions to ensure compliance with regulatory standards before granting approval for market authorization and distribution within the country.